MAPT and Alzheimer disease: We further evaluate if BD-tau concentrations increase as a function of combined A+ and N+ abnormalities in the AD continuum, and if such an A/N classification can be implemented using blood-based biomarkers to identify those at short-term risk for cognitive decline and atrophy.